For fiscal 2023, Knight has updated its financial guidance on revenues and expects to generate between C$325 million to C$335 million in revenues an increase of C$15 million on the lower end and C$5 million on the upper end of the range. The adjusted EBITDA is expected to be approximately 18% of revenues. The increase in the financial outlook is primarily due to the Q4-23 MOH Order, as well as improvement in forecasted LATAM currencies against the Canadian dollar.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KHTRF:
- Knight Therapeutics Reports Third Quarter 2023 Results
- Is KHTRF a Buy, Before Earnings?
- Knight Therapeutics announces CMED price approval of Minjuvi in Brazil
- Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
- Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil